On January 25, Hybio Pharmaceutical Co.Ltd(300199) announced that Yuan Jiancheng, the former director and President, had been approved for arrest on suspicion of job-related crimes, and Zhu Wenfeng, the former director, Secretary of the board of directors and vice president, had been criminally detained on suspicion of job-related embezzlement. Hybio Pharmaceutical Co.Ltd(300199) did not specifically disclose in the announcement, but only said that it was related to the two during their tenure, and more than 36 million yuan of job-related crime funds involved in Yuan Jiancheng have been recovered. Hybio Pharmaceutical Co.Ltd(300199) said it would fully cooperate with the public security and judicial organs in the investigation of the above cases and try its best to recover the losses of the company.
High level "big change", determine the strategy of combining imitation and innovation, and accelerate innovation and transformation... Under the leadership of the new team, Hybio Pharmaceutical Co.Ltd(300199) can break the situation and usher in a new period of development?
Hanyu high-level "blood exchange"
Hybio Pharmaceutical Co.Ltd(300199) is a national high-tech enterprise specializing in the R & D, production and sales of polypeptide drugs. It is a leading enterprise in the field of polypeptide in China. Its main products include six series: characteristic API, customized peptide, injection, solid preparation, drug combination packaging products and medical device products. In 2011, Hybio Pharmaceutical Co.Ltd(300199) was listed on the gem. As of the first half of 2021, it has 24 polypeptide drugs, 9 new drug certificates and 17 clinical approvals.
According to the listing prospectus of Hybio Pharmaceutical Co.Ltd(300199) 2011, Yuan Jiancheng is 59 years old and graduated from medicine. He has focused on the application research of polypeptide drugs in clinic since 1990 and studied in the United States. After returning to China, Yuan Jiancheng served as the deputy director of the military Burn Research Institute of the Third Military Medical University. He officially entered Hanyu in 2004 and became the president of Hybio Pharmaceutical Co.Ltd(300199) in 2009 until he resigned in August 2019.
Zhu Wenfeng, 44, took over as the Secretary of the company in April 2016 and served as the vice president of the company after the resignation of the former Secretary of the company. According to his resume, he didn't work in Hybio Pharmaceutical Co.Ltd(300199) before, but worked in the media and worked as a reporter and independent producer successively.
According to the announcement released by Hybio Pharmaceutical Co.Ltd(300199) in January 2021, the Shenzhen Stock Exchange has conducted on-site inspection on it since August 2020 and found a series of problems, including non-standard operation of the board of directors and the general meeting of shareholders, untimely information disclosure, internal control and financial accounting. The time of the problems is mainly from 2016 to 2019. On January 4, 2021, Shenzhen Securities Regulatory Bureau issued the decision on administrative supervision measures to Hybio Pharmaceutical Co.Ltd(300199) and relevant personnel, took administrative supervision measures to order Hybio Pharmaceutical Co.Ltd(300199) to make corrections, and issued a warning letter to four current directors / senior managers, including yuan Jiancheng and Zhu Wenfeng.
The relevant person in charge told the Beijing news that after Yuan Jiancheng resigned, the company found that the above two people were suspected of job occupation in its self-examination, and finally called the police. "Judging from the progress of the case, the cases of Yuan Jiancheng and Zhu Wenfeng are independent cases. The specific amount involved depends on the final determination of the procuratorate." The person in charge said that the compliance management department was independent last year and was in the charge of the chairman in person, so as to realize the supervision of professional managers and avoid the recurrence of self-management and self-examination. In addition, in the original senior management team, except that Yu Pinxiang, vice president, served as the executive president and was responsible for important work such as daily operation, strategic planning and goal setting, almost all the rest "changed their blood".
imitation innovation combination accelerates transformation
After the listing of Hybio Pharmaceutical Co.Ltd(300199) in 2011, the net profit attributable to the shareholders of the listed company (hereinafter referred to as "net profit") once increased from 80.4744 million yuan in 2011 to 330 million yuan in 2017. In 2018, the net profit decreased by 203.35% year-on-year, and the net profit was - 341 million yuan, mainly due to the provision for goodwill impairment of 529 million yuan. In 2019 and 2020, Hybio Pharmaceutical Co.Ltd(300199) sustained losses, with net profits of - 885 million yuan and - 609 million yuan respectively.
In 2021, Hybio Pharmaceutical Co.Ltd(300199) performance forecast shows that the net profit attributable to shareholders of listed companies is expected to be 25 million yuan to 37.5 million yuan, and the net profit after deduction is expected to be - 430 million yuan to - 380 million yuan. "Before that, we took the road of generic drugs. Last year, we determined the strategy of combining generic drugs with innovation, accelerated the layout of innovative drugs, and hoped to usher in a break in the dilemma." The above person in charge said that the company has trained a group of R & D personnel in echelon, recruited many doctors and postdoctors, and established an innovation department precisely to accelerate innovation transformation.
In the previous announcement, Hybio Pharmaceutical Co.Ltd(300199) said that it had increased the research and development of innovative drugs, and a number of class I new drugs had entered the research and development pipeline in anti-tumor and other fields. One of the most concerned is the covid-19 virus polypeptide nasal spray developed by Hybio Pharmaceutical Co.Ltd(300199) in cooperation with the Institute of Microbiology, Chinese Academy of Sciences.
On November 13, 2021, Hybio Pharmaceutical Co.Ltd(300199) said that in the cooperation between the two sides, six polypeptide sequences in the patent application technology of "a polypeptide against covid-19 virus and its application" of the Institute of Microbiology of the Chinese Academy of Sciences were licensed to Hybio Pharmaceutical Co.Ltd(300199) in the form of global exclusive license. In the following two trading days, Hybio Pharmaceutical Co.Ltd(300199) share price rose by more than 30%. On January 20 this year, it rose to 22.1 yuan / share, with a cumulative increase of 137.35%. In recent trading days, the share price began to callback. As of the closing on January 26 this year, the share price callback to 12.24 yuan / share. "From the stock price, we can see the market's recognition of innovation. This project may be an important step to determine the future development of Hanyu." The official said.
On January 23 this year, the official wechat content released by Hybio Pharmaceutical Co.Ltd(300199) also showed that covid-19 polypeptide nasal spray drug project had urgently completed the joint application of relevant patents China and international (PCT patents) on December 31, 2021. The project team mobilized various resources, overcome various problems, and made every effort to promote the progress of the project at full speed. The large-scale production of API, preparation research, clinical related work and subsequent preliminary preparations for industrialization have entered a tense state of work.
It remains to be seen whether Hybio Pharmaceutical Co.Ltd(300199) trying to break the situation in the dilemma can finally usher in the rapid progress of performance.
